Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)

Antoni Sicras-Mainar; Ruth Navarro-Artieda

doi:10.4093/dmj.2015.39.2.173

Articles

Page Path: HOME > Diabetes Metab J > Volume 39(2); 2015 > Article

Response Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81): Antoni Sicras-Mainar¹, Ruth Navarro-Artieda²; Diabetes & Metabolism Journal 2015;39(2):173-174.
DOI: https://doi.org/10.4093/dmj.2015.39.2.173
Published online: April 20, 2015

2,248 Views
24 Download

¹Management Planning, Badalona Serveis Assistencials SA, Barcelona, Spain.

²Medical Documentation, Hospital Germans Trias i Pujol, Barcelona, Spain.

Corresponding author: Antoni Sicras-Mainar. Management Planning, Badalona Serveis Assistencials SA, C. Gaietà Soler, 6-8 entlo, 08911 Badalona, Barcelona, Spain. asicras@bsa.cat

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

NOTES
REFERENCES

We appreciate your interest and comments on our article entitled "Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in Spanish patients" which was published in Diabetes & Metabolism Journal [1].

It is correct that the objective of the study was to determine resource use and the resulting costs of the combination of meformin with dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment (RI) in real clinical practice. We made a retrospective observational study which included 395 patients aged ≥30 years receiving metformin who initiated a second oral treatment with DPP-4 inhibitors or other oral antidiabetics (reference group). The follow-up was 2 years. The study concluded that, in spite of the study limitations, patients with RI receiving metformin and DPP-4 inhibitors and had a greater probability of achieving better metabolic control and lower rates of hyperglycemia, and resulted in lower health costs for the Spanish National Health System [1].

In response to the authors, we would underline that we were not evaluating the total cost of treatment, but rather the total cost of the patients receiving treatment. Therefore it is necessary to be extremely cautious about the external validity and the causality of the observations (see the limitations of the study). The cost of medications was greater in the reference group, and this was due to the fact that these patients received more drugs related to complications (hyperglycemia, cardiovascular events, etc.) occurring during the study follow-up. It is true that the unit costs of DPP-4 inhibitors are greater than those of other oral antidiabetics, and we are grateful for this comment. We also agree that using the initial level of glycosylated hemoglobin might be more appropriate to compare the general effect in the reduction of glucose levels in each group. However, all patients in both groups were receiving double therapy, and we therefore consider that differences in clinical effects were not very consistent and not very representative of disease progression.

DPP-4 inhibitors act by increasing the effect of native glucagon-like peptide-1 which stimulate the secretion of insulin by pancreatic β-cells and inhibit the secretion of glucagon by α cells [2]. DDP-4 inhibitors may be an alternative to sulfonylureas in patients with a high risk of hyperglycemia in whom metformin is insufficient to achieve glycemic control [3,4,5]. Further studies in real life conditions will be necessary to confirm the consistency of our results.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Sicras-Mainar A, Navarro-Artieda R. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients. Diabetes Metab J 2015;39:74-81. Article PubMed PMC
2. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2013;28:262-274. Article PubMed PMC
3. Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf 2014;5:138-146. Article PubMed PMC PDF
4. Liu Y, Hu Y. Novel DPP-4 inhibitors against diabetes. Future Med Chem 2014;6:793-808. Article PubMed
5. Davidson MH. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med 2014;126:56-65. Article PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)

Diabetes Metab J. 2015;39(2):173-174. Published online April 20, 2015

DOI: https://doi.org/10.4093/dmj.2015.39.2.173

XML Download